FDA Rejects Pair Of Gilead HIV Drugs
The drugs already are approved as components of Gilead's HIV treatment Stribild, a once-a-day tablet made up of elvitegravir and cobicistat as well as emtricitabine and tenofovir disoproxil fumarate. The company said the decision will not affect its marketing of Stribild.
The FDA told Gilead it had found “deficiencies in documentation and validation of...
To view the full article, register now.